R&D channel feed – Endpoints News

R&D channel feed

Gut check: Newest microbiome startup concentrates on autism, Parkinson’s disease

9 years ago

Investigators prep PhIII in effort to move MDMA (you know it as ecstasy) off the street and into use for PTSD

9 years ago

Fresh enthusiasm for Cerecor sours as lead drug flops in PhII depression study, shares crater

9 years ago

Hot on the heels of a clinical hold, Arrowhead torches its clinical pipeline, slashes staff

9 years ago

Step aside AstraZeneca, Pfizer/Merck KGaA jump ahead, getting a speedy review for their checkpoint rival avelumab

9 years ago

AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro

9 years ago

Nivalis shares in meltdown as cystic fibrosis promise withers in PhII flop

9 years ago

Amicus maps out a 3-year delay at the FDA for lead drug, sending shares into a tailspin

9 years ago

Tired of being dumped by pharma partners, Vanderbilt’s neuroscience team takes a bold aim at the clinic

9 years ago

Will J&J come up with a big enough treasure trove to win an Actelion buyout?

9 years ago

Two more patients die as Juno’s lead CAR-T turns lethal again; trial halted

9 years ago

GSK targets a new indication for Nucala, flags PhIII success for a rare disease

9 years ago

It’s over: Eli Lilly shares tank after its huge gamble on Alzheimer’s drug solanezumab ends in failure

9 years ago

Ex-Allergan prez Ingram forges $1B deal to sell Alzheimer’s biotech to Brent Saunders and the new crew at Allergan

9 years ago

Thinking bigger, Arch Venture closes in on $550M-plus biotech fund

9 years ago

Eau de poop: Bill Gates tests a new way to sweeten the world’s worst odors

9 years ago

Booming rare disease player Shire adding a trendy new R&D hub in Kendall Square for 1,000-plus

9 years ago

It’s a tie: Sanofi and Novo come in neck-and-neck at the FDA with two new diabetes combo OKs

9 years ago

After a painful stumble, AstraZeneca gets top checkpoint cancer program back on track

9 years ago

Aduro gets back on track with CRS-207 after FDA lifts partial clinical hold

9 years ago

Chiesi picks a pipeline fight with Novartis, going head-to-head on a big new target for asthma

9 years ago

Acorda writes off another R&D program as Ampyra flops in stroke study

9 years ago

MD Anderson to biotech billionaire Soon-Shiong: Get your own slogan. ‘Moon Shots’ belongs to us

9 years ago

Gilead punts hep B drug as GlobeImmune joins the (dead quiet) ranks of zombie biotechs

9 years ago

First page Previous page 311 312 313314315 316 317 Next page Last page